Core Viewpoint - Shanhe Pharmaceutical Excipients Co., Ltd. has recently received a registration number for a new pharmaceutical excipient product, Mannitol Pill Core, from the National Medical Products Administration (NMPA) [1] Company Summary - Shanhe Pharmaceutical Excipients has a total of 47 products that have received registration numbers from the NMPA as of the announcement date [1] - The newly registered Mannitol Pill Core is made from D-mannitol and other excipients, and is primarily used as a carrier for enteric-coated micro-pellets and sustained-release micro-pellets, and can also be used directly as a drug micro-pellet [1]

Core Viewpoint - The company Shanhe Pharmaceutical Auxiliary (300452.SZ) has announced the registration of a new pharmaceutical excipient product, Mannitol Core, with the National Medical Products Administration (NMPA) [1] Group 1 - The newly registered product, Mannitol Core, has the registration number F20250000241 [1] - Mannitol Core is composed of D-mannitol and other excipients, characterized as white or off-white spherical granules [1] - The primary applications of Mannitol Core include serving as a carrier for enteric-coated microgranules and sustained-release microgranules, and it can also be used directly as a drug microgranule [1]

证券代码:300452 证券简称:山河药辅 公告编号：2025-043 债券代码:123199 债券简称:山河转债 公司新增产品品种，扩大了公司产品生产范围,将对公司后续年 度的经营产生一定的积极影响。同时敬请广大投资者谨慎投资，注意 防范投资风险。 特此公告。 安徽山河药用辅料股份有限公司 关于公司新增产品品种的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 近日安徽山河药用辅料股份有限公司（以下简称"山河药辅"或 "公司"）新增 1 种药用辅料产品：甘露醇丸芯获得国家药品监督管 理局药品审评中心（以下简称"CDE"）的登记号，为 F20250000241。 截止公告日，山河药辅已有 47 种产品获得 CDE 登记号，详情登陆 CD E 官网（http://www.cde.org.cn/）查询。 根据国家药品监督管理局发布公告称，为贯彻落实中共中央办公 厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创 新的意见》（厅字〔2017〕42 号）与《国务院关于取消一批行政许 可事项的决定》（国发〔2017〕46 号），各级食品药品监督管理部 门不再单独受理原料 ...

每经AI快讯，山河药辅（SZ 300452，最新价：14元）7月31日晚间发布公告称，公司第六届第六次董事 会会议于2025年7月31日在公司三楼会议室召开。会议审议了《关于修订 <董事会议事规则> 的议案》 等文件。 2024年1至12月份，山河药辅的营业收入构成为：医药制造业占比100.0%。 每经头条（nbdtoutiao）——"我们也深陷残酷价格战"！德资巨头中国区高管警告：智驾绝不能免费， 否则会给全行业带来灾难 （记者 王瀚黎） ...

Group 1 - The core viewpoint of the news is that Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. has shown a slight increase in revenue but a decrease in net profit in its latest quarterly report [1] - As of August 1, 2025, the company's stock price closed at 14.31 yuan, down 2.32%, with a trading volume of 239,600 hands and a transaction amount of 353 million yuan [1] - The company's main funds experienced a net outflow of 13.46 million yuan, accounting for 3.82% of the transaction amount, with significant outflows from large orders [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 248 million yuan, a year-on-year increase of 4.28%, while the net profit attributable to shareholders decreased by 5.30% to 47.18 million yuan [1] - The company has a current ratio of 4.936, a quick ratio of 4.556, and a debt-to-asset ratio of 35.72% [1] - Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. was established in 2001 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of approximately 2.34 billion yuan [1][2]

Key Points - The article highlights significant announcements from various companies, including investment projects, performance data, and share buybacks [1][2] Company Announcements - Anzheng Fashion's controlling company, Lishang Information, has not engaged in the production of maternal and infant products [1] - New Aluminum Era plans to invest in a project to produce 800,000 sets of lightweight, high-strength auto parts annually [1] - Wanlima is expected to win a procurement project from China Southern Airlines [1] - Guangzhou Port anticipates a cargo throughput of 50.233 million tons in July, reflecting a year-on-year increase of 3.1% [1] - Shenma Co. intends to acquire a 10.27% minority stake in Nylon Chemical [1] - Fuanna plans to repurchase shares worth between 55.85 million to 104 million yuan [1] - Zhengdan Co. reported a 120.35% year-on-year increase in net profit for the first half of the year and plans to distribute 3 yuan per 10 shares [1] - Jieya Co. and Heyuan Gas's major shareholders plan to reduce their stakes by up to 4.95% and 2%, respectively [1][2] - Changhua Chemical aims to raise no more than 230 million yuan through a simplified procedure for a carbon dioxide polyether project [1] - Aoshikang plans to issue convertible bonds to raise no more than 1 billion yuan for a high-end printed circuit board project [1] Performance Data - Zhengdan Co. expects a significant increase in net profit for the first half of the year, with a proposed dividend distribution [2] - Jiejia Weichuang anticipates a net profit increase of 38.65% to 59.85% for the half-year [2] - Sinopec forecasts a 39.5% to 43.7% decline in net profit for the first half of the year [2]

Core Viewpoint - The company held its sixth board meeting on July 31, 2025, where several key resolutions were passed, including the reappointment of the auditing firm and the signing of an investment agreement for a new project [1][2][3]. Group 1: Audit and Governance - The board approved the reappointment of Rongcheng Accounting Firm for the 2025 annual audit, with the management authorized to negotiate the audit fees based on various factors [1][2]. - The board proposed to increase the number of board members from 7 to 8, adding one employee representative director while maintaining the number of independent directors at 3 [3][4]. - The board also approved the formulation and revision of several corporate governance systems, which will be submitted for shareholder approval [4]. Group 2: Project Investment - The board agreed to sign an investment cooperation agreement with the Huainan Economic and Technological Development Zone Management Committee for a high-end auxiliary material manufacturing base project [2][3]. - This investment agreement will also require shareholder approval at the upcoming extraordinary general meeting [2][3]. Group 3: Shareholder Meeting - The board scheduled the 2025 first extraordinary general meeting for August 18, 2025, to review the resolutions passed during the board meeting [4].

Core Viewpoint - The company announced the approval of the proposal to reappoint the auditing firm for the fiscal year 2025 during the sixth meeting of the sixth supervisory board [2] Group 1 - The sixth supervisory board meeting of the company took place on July 31 [2] - The proposal regarding the reappointment of the auditing institution was among the key items discussed and approved [2]

（文章来源：证券日报） 证券日报网讯 7月31日晚间，山河药辅发布公告称，公司第六届董事会第六次会议审议通过了《关于续 聘2025年度审计机构的议案》等多项议案。 ...

Core Viewpoint - The company, Shanhe Pharmaceutical Auxiliary (300452), announced that it will hold its first extraordinary general meeting of shareholders for 2025 on August 18, 2025, to review the proposal for the reappointment of the auditing institution for the fiscal year 2025 [1] Group 1 - The extraordinary general meeting is scheduled for August 18, 2025 [1] - The agenda includes the review of the proposal regarding the reappointment of the auditing institution for the year 2025 [1]